Heron Reports Q4 Revenue of $40.588M, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy HRTX?
Reports Q4 revenue $40.588M, consensus $39.53M. "As demonstrated in today's release, we are entering 2026 with exceptional momentum. The fourth quarter delivered the strongest results in the history of Heron's Acute Care franchise, underscoring the success of the strategic decisions we implemented to unlock the full potential of these assets," said Craig Collard, Chief Executive Officer of Heron. "The milestones achieved in 2025, particularly for ZYNRELEF - including enhanced distributor-partner incentives, the seamless completion of the Vial Access Needle transition, and CMS approval of a product-specific J-Code - are already accelerating adoption and strengthening our competitive position in a large and underpenetrated market."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HRTX
Wall Street analysts forecast HRTX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.190
Low
3.00
Averages
4.50
High
6.00
Current: 1.190
Low
3.00
Averages
4.50
High
6.00
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Heron (HRTX) Q4 2025 Earnings Call Transcript
See More
Heron Therapeutics Q4 2025 Earnings Highlights
- Successful Financing Completion: CEO Craig Collard emphasized the successful completion of financing, describing it as a 'meaningful derisking event' that allows the company to focus on commercial execution and product expansion, thereby driving sustained growth.
- Strong Financial Performance: Full-year net revenues for 2025 reached approximately $155 million, with adjusted EBITDA of $14.7 million, exceeding prior guidance of $9 million to $13 million, showcasing the company's financial robustness and growth potential.
- Acute Care Product Line Growth: ZYNRELEF achieved a 48% net revenue growth in Q4, while APONVIE grew by 97%, leading to an overall year-over-year increase of over 57% in the Acute Care franchise, indicating the company's strengthening competitive position in the market.
- Optimistic 2026 Outlook: Management raised the 2026 net product sales guidance to $173 million to $183 million, with expectations of EBITDA positivity, reflecting confidence in commercial expansion and the strategic necessity of targeted investments.
See More
Heron Therapeutics Q4 Earnings Report Analysis
- Earnings Performance: Heron Therapeutics reported a Q4 GAAP EPS of -$0.02, missing estimates by $0.01, although revenue reached $40.59 million, a slight 0.5% year-over-year decline, yet exceeding market expectations by $1.06 million, indicating some effectiveness in revenue management.
- Acute Care Growth: The Acute Care franchise achieved a remarkable 57.3% year-over-year revenue growth in Q4 2025 and 65.1% for the full year compared to 2024, suggesting strong market demand in this segment, potentially laying the groundwork for sustained future growth.
- Cash Position: As of December 31, 2025, Heron reported cash, cash equivalents, and short-term investments totaling $46.6 million, reflecting robust liquidity management that supports future operations and investments.
- 2026 Financial Guidance: Heron provided a 2026 net revenue guidance of $173 to $183 million and an adjusted EBITDA forecast of $10 to $20 million, both exceeding the consensus estimate of $171.73 million, demonstrating the company's confidence in its future performance.
See More
Heron Therapeutics to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Heron Therapeutics (HRTX) is set to announce its Q4 2023 earnings on February 26 before the market opens, drawing significant attention from investors regarding its performance.
- Earnings Expectations: The consensus EPS estimate stands at -$0.03, indicating potential profitability challenges that could affect investor confidence in the company's financial health.
- Revenue Projections: The revenue estimate is $39.53 million, reflecting a 3.1% year-over-year decline, which suggests that the company is facing challenges in a competitive market environment that may impact future growth prospects.
- Historical Performance Review: Over the past year, HRTX has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, indicating that the company has a track record of exceeding expectations to some extent.
See More
Heron Therapeutics Reports Q4 2025 Net Revenue of $40.5M Driven by ZYNRELEF and APONVIE
- Revenue Growth: Heron Therapeutics reported approximately $40.5 million in net revenue for Q4 2025, reflecting significant growth compared to the previous year, driven particularly by strong momentum in its Acute Care franchise, especially ZYNRELEF and APONVIE.
- Product Performance: ZYNRELEF generated approximately $12.5 million in net revenue in Q4, marking the largest quarter-over-quarter revenue increase within the portfolio, indicating successful market acceptance and sales strategies.
- Diversified Revenue Streams: CINVANTI and APONVIE contributed approximately $22.9 million and $3.8 million in net revenue for Q4, respectively, enhancing the diversity of the company's revenue sources and reducing reliance on any single product.
- Annual Performance: Total net revenue for FY25 was approximately $154.9 million, reflecting ongoing progress and growth potential across all business areas, suggesting a positive outlook for future developments.
See More
Heron Therapeutics Reports $154.9M Net Revenue for 2025
- Revenue Growth: Heron Therapeutics reported approximately $40.5 million in net revenue for Q4 2025, reflecting strong momentum in its Acute Care franchise, particularly driven by ZYNRELEF® and APONVIE®.
- Product Performance: ZYNRELEF® generated about $12.5 million in net revenue in Q4, marking a ~35% increase from Q3, indicating sustained demand in the postoperative pain management market and enhancing the company's competitive edge.
- Diversified Revenue Streams: CINVANTI® and SUSTOL® achieved net revenues of approximately $22.9 million and $1.3 million in Q4, respectively, further solidifying Heron's market position in the prevention of chemotherapy-induced nausea and vomiting.
- Strategic Outlook: With total net revenue of approximately $154.9 million for 2025, Heron demonstrates ongoing innovation and market expansion capabilities in the biotechnology sector, laying a solid foundation for future growth.
See More
Heron (HRTX) Q4 2025 Earnings Call Transcript
See More
Heron Therapeutics Q4 2025 Earnings Highlights
- Successful Financing Completion: CEO Craig Collard emphasized the successful completion of financing, describing it as a 'meaningful derisking event' that allows the company to focus on commercial execution and product expansion, thereby driving sustained growth.
- Strong Financial Performance: Full-year net revenues for 2025 reached approximately $155 million, with adjusted EBITDA of $14.7 million, exceeding prior guidance of $9 million to $13 million, showcasing the company's financial robustness and growth potential.
- Acute Care Product Line Growth: ZYNRELEF achieved a 48% net revenue growth in Q4, while APONVIE grew by 97%, leading to an overall year-over-year increase of over 57% in the Acute Care franchise, indicating the company's strengthening competitive position in the market.
- Optimistic 2026 Outlook: Management raised the 2026 net product sales guidance to $173 million to $183 million, with expectations of EBITDA positivity, reflecting confidence in commercial expansion and the strategic necessity of targeted investments.
See More
Heron Therapeutics Q4 Earnings Report Analysis
- Earnings Performance: Heron Therapeutics reported a Q4 GAAP EPS of -$0.02, missing estimates by $0.01, although revenue reached $40.59 million, a slight 0.5% year-over-year decline, yet exceeding market expectations by $1.06 million, indicating some effectiveness in revenue management.
- Acute Care Growth: The Acute Care franchise achieved a remarkable 57.3% year-over-year revenue growth in Q4 2025 and 65.1% for the full year compared to 2024, suggesting strong market demand in this segment, potentially laying the groundwork for sustained future growth.
- Cash Position: As of December 31, 2025, Heron reported cash, cash equivalents, and short-term investments totaling $46.6 million, reflecting robust liquidity management that supports future operations and investments.
- 2026 Financial Guidance: Heron provided a 2026 net revenue guidance of $173 to $183 million and an adjusted EBITDA forecast of $10 to $20 million, both exceeding the consensus estimate of $171.73 million, demonstrating the company's confidence in its future performance.
See More
Heron Therapeutics to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Heron Therapeutics (HRTX) is set to announce its Q4 2023 earnings on February 26 before the market opens, drawing significant attention from investors regarding its performance.
- Earnings Expectations: The consensus EPS estimate stands at -$0.03, indicating potential profitability challenges that could affect investor confidence in the company's financial health.
- Revenue Projections: The revenue estimate is $39.53 million, reflecting a 3.1% year-over-year decline, which suggests that the company is facing challenges in a competitive market environment that may impact future growth prospects.
- Historical Performance Review: Over the past year, HRTX has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, indicating that the company has a track record of exceeding expectations to some extent.
See More
Heron Therapeutics Reports Q4 2025 Net Revenue of $40.5M Driven by ZYNRELEF and APONVIE
- Revenue Growth: Heron Therapeutics reported approximately $40.5 million in net revenue for Q4 2025, reflecting significant growth compared to the previous year, driven particularly by strong momentum in its Acute Care franchise, especially ZYNRELEF and APONVIE.
- Product Performance: ZYNRELEF generated approximately $12.5 million in net revenue in Q4, marking the largest quarter-over-quarter revenue increase within the portfolio, indicating successful market acceptance and sales strategies.
- Diversified Revenue Streams: CINVANTI and APONVIE contributed approximately $22.9 million and $3.8 million in net revenue for Q4, respectively, enhancing the diversity of the company's revenue sources and reducing reliance on any single product.
- Annual Performance: Total net revenue for FY25 was approximately $154.9 million, reflecting ongoing progress and growth potential across all business areas, suggesting a positive outlook for future developments.
See More
Heron Therapeutics Reports $154.9M Net Revenue for 2025
- Revenue Growth: Heron Therapeutics reported approximately $40.5 million in net revenue for Q4 2025, reflecting strong momentum in its Acute Care franchise, particularly driven by ZYNRELEF® and APONVIE®.
- Product Performance: ZYNRELEF® generated about $12.5 million in net revenue in Q4, marking a ~35% increase from Q3, indicating sustained demand in the postoperative pain management market and enhancing the company's competitive edge.
- Diversified Revenue Streams: CINVANTI® and SUSTOL® achieved net revenues of approximately $22.9 million and $1.3 million in Q4, respectively, further solidifying Heron's market position in the prevention of chemotherapy-induced nausea and vomiting.
- Strategic Outlook: With total net revenue of approximately $154.9 million for 2025, Heron demonstrates ongoing innovation and market expansion capabilities in the biotechnology sector, laying a solid foundation for future growth.
See More
